Patient characteristics
| Characteristic . | Entire cohort . | TCD HCT . | T-replete–T . | DUCB-T . |
|---|---|---|---|---|
| N (%) . | n (%) . | n (%) . | n (%) . | |
| Total N = 267 . | Total n = 119 . | Total n = 96 . | Total n = 52 . | |
| Age | ||||
| Median (range), y | 53.6 (21.1-73.9) | 55.7 (21.4-70.8) | 54.3 (24-73.9) | 50.8 (21.1-69.9) |
| Gender | ||||
| Female | 103 (38.6%) | 47 (39.5%) | 31 (32.3%) | 25 (48.1%) |
| Male | 164 (61.4%) | 72 (60.5%) | 65 (67.7%) | 27 (51.9%) |
| CMV serostatus (recipient [R]/donor [D]) | ||||
| R+/D+ | 73 (27.3%) | 32 (26.9%) | 41 (42.7%) | 0 (0%) |
| R+/D− | 93 (34.8%) | 38 (31.9%) | 20 (20.8%) | 34 (65.4%) |
| R−/D+ | 25 (9.4%) | 14 (11.8%) | 12 (12.5%) | 0 (0%) |
| R−/D− | 76 (28.5%) | 35 (29.4%) | 23 (24%) | 18 (34.6%) |
| CMV reactivation | ||||
| Yes | 129 (48.3%) | 57 (47.9%) | 47 (49%) | 25 (48.1%) |
| No | 138 (51.7%) | 62 (52.1%) | 49 (51%) | 27 (51.9%) |
| Underlying disease | ||||
| Acute leukemia | 123 (46.1%) | 58 (48.7%) | 33 (34.4%) | 32 (61.5%) |
| Chronic leukemia | 20 (7.5%) | 5 (4.2%) | 9 (9.4%) | 5 (9.6%) |
| Myelodysplastic syndrome | 34 (12.7%) | 26 (21.8%) | 7 (7.3%) | 1 (1.9%) |
| Multiple myeloma | 24 (9%) | 23 (19.3%) | 1 (1%) | 0 (0%) |
| Hodgkin disease | 7 (2.6%) | 0 (0%) | 5 (5.2%) | 2 (3.8%) |
| Non-Hodgkin lymphoma | 44 (16.5%) | 1 (0.8%) | 32 (33.3%) | 11 (21.2%) |
| Other∗ | 15 (5.6%) | 6 (5%) | 9 (9.4%) | 1 (1.9%) |
| Conditioning regimen | ||||
| Busulfan based | 107 (40.1%) | 86 (72.3%) | 21 (21.9%) | 0 (0%) |
| Carmustine/etoposide/cytarabine/melphalan | 1 (0.4%) | 0 (0%) | 1 (1%) | 0 (0%) |
| Clofarabine/thio-TEPA/melphalan | 10 (3.7%) | 6 (5%) | 4 (4.2%) | 0 (0%) |
| Cyclophosphamide/fludarabine/TBI | 46 (17.2%) | 0 (0%) | 30 (31.3%) | 16 (30.8%) |
| Cyclophosphamide/fludarabine/thio-TEPA/TBI | 40 (15%) | 0 (0%) | 5 (5.2%) | 35 (67.3%) |
| Fludarabine/melphalan | 27 (10.1%) | 0 (0%) | 26 (27.1%) | 1 (1.9%) |
| Fludarabine/TBI | 1 (0.4%) | 0 (0%) | 1 (1%) | 0 (0%) |
| High-dose TBI based | 35 (13.1%) | 27 (22.7%) | 8 (8.3%) | 0 (0%) |
| GVHD prophylaxis | ||||
| Calcineurin inhibitor/methotrexate with/without sirolimus | 96 (35.9%) | 0 | 96 (100%) | 0 |
| CSA/MMF | 52 (19.5%) | 0 | 0 | 52 (100%) |
| Donor type | ||||
| Matched related | 79 (29.6%) | 44 (37%) | 35 (36.5%) | 0 (0%) |
| Matched unrelated† | 99 (37.1%) | 45 (37.8%) | 54 (56.3%) | 0 (0%) |
| Mismatched | 89 (33.3%) | 30 (25.2%) | 7 (7.3%) | 52 (100%) |
| Characteristic . | Entire cohort . | TCD HCT . | T-replete–T . | DUCB-T . |
|---|---|---|---|---|
| N (%) . | n (%) . | n (%) . | n (%) . | |
| Total N = 267 . | Total n = 119 . | Total n = 96 . | Total n = 52 . | |
| Age | ||||
| Median (range), y | 53.6 (21.1-73.9) | 55.7 (21.4-70.8) | 54.3 (24-73.9) | 50.8 (21.1-69.9) |
| Gender | ||||
| Female | 103 (38.6%) | 47 (39.5%) | 31 (32.3%) | 25 (48.1%) |
| Male | 164 (61.4%) | 72 (60.5%) | 65 (67.7%) | 27 (51.9%) |
| CMV serostatus (recipient [R]/donor [D]) | ||||
| R+/D+ | 73 (27.3%) | 32 (26.9%) | 41 (42.7%) | 0 (0%) |
| R+/D− | 93 (34.8%) | 38 (31.9%) | 20 (20.8%) | 34 (65.4%) |
| R−/D+ | 25 (9.4%) | 14 (11.8%) | 12 (12.5%) | 0 (0%) |
| R−/D− | 76 (28.5%) | 35 (29.4%) | 23 (24%) | 18 (34.6%) |
| CMV reactivation | ||||
| Yes | 129 (48.3%) | 57 (47.9%) | 47 (49%) | 25 (48.1%) |
| No | 138 (51.7%) | 62 (52.1%) | 49 (51%) | 27 (51.9%) |
| Underlying disease | ||||
| Acute leukemia | 123 (46.1%) | 58 (48.7%) | 33 (34.4%) | 32 (61.5%) |
| Chronic leukemia | 20 (7.5%) | 5 (4.2%) | 9 (9.4%) | 5 (9.6%) |
| Myelodysplastic syndrome | 34 (12.7%) | 26 (21.8%) | 7 (7.3%) | 1 (1.9%) |
| Multiple myeloma | 24 (9%) | 23 (19.3%) | 1 (1%) | 0 (0%) |
| Hodgkin disease | 7 (2.6%) | 0 (0%) | 5 (5.2%) | 2 (3.8%) |
| Non-Hodgkin lymphoma | 44 (16.5%) | 1 (0.8%) | 32 (33.3%) | 11 (21.2%) |
| Other∗ | 15 (5.6%) | 6 (5%) | 9 (9.4%) | 1 (1.9%) |
| Conditioning regimen | ||||
| Busulfan based | 107 (40.1%) | 86 (72.3%) | 21 (21.9%) | 0 (0%) |
| Carmustine/etoposide/cytarabine/melphalan | 1 (0.4%) | 0 (0%) | 1 (1%) | 0 (0%) |
| Clofarabine/thio-TEPA/melphalan | 10 (3.7%) | 6 (5%) | 4 (4.2%) | 0 (0%) |
| Cyclophosphamide/fludarabine/TBI | 46 (17.2%) | 0 (0%) | 30 (31.3%) | 16 (30.8%) |
| Cyclophosphamide/fludarabine/thio-TEPA/TBI | 40 (15%) | 0 (0%) | 5 (5.2%) | 35 (67.3%) |
| Fludarabine/melphalan | 27 (10.1%) | 0 (0%) | 26 (27.1%) | 1 (1.9%) |
| Fludarabine/TBI | 1 (0.4%) | 0 (0%) | 1 (1%) | 0 (0%) |
| High-dose TBI based | 35 (13.1%) | 27 (22.7%) | 8 (8.3%) | 0 (0%) |
| GVHD prophylaxis | ||||
| Calcineurin inhibitor/methotrexate with/without sirolimus | 96 (35.9%) | 0 | 96 (100%) | 0 |
| CSA/MMF | 52 (19.5%) | 0 | 0 | 52 (100%) |
| Donor type | ||||
| Matched related | 79 (29.6%) | 44 (37%) | 35 (36.5%) | 0 (0%) |
| Matched unrelated† | 99 (37.1%) | 45 (37.8%) | 54 (56.3%) | 0 (0%) |
| Mismatched | 89 (33.3%) | 30 (25.2%) | 7 (7.3%) | 52 (100%) |